CA3143711A1 - Azacitidine in combination with venetoclax, gilteritinib, midostaurin or other compounds for treating leukemia or myelodysplastic syndrome - Google Patents
Azacitidine in combination with venetoclax, gilteritinib, midostaurin or other compounds for treating leukemia or myelodysplastic syndrome Download PDFInfo
- Publication number
- CA3143711A1 CA3143711A1 CA3143711A CA3143711A CA3143711A1 CA 3143711 A1 CA3143711 A1 CA 3143711A1 CA 3143711 A CA3143711 A CA 3143711A CA 3143711 A CA3143711 A CA 3143711A CA 3143711 A1 CA3143711 A1 CA 3143711A1
- Authority
- CA
- Canada
- Prior art keywords
- azacytidine
- days
- dose
- therapeutic agent
- additional therapeutic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
- A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2/00—Disinfection or sterilisation of materials or objects, in general; Accessories therefor
- A61L2/16—Disinfection or sterilisation of materials or objects, in general; Accessories therefor using chemical substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2103/00—Materials or objects being the target of disinfection or sterilisation
- A61L2103/05—Living organisms or biological materials
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Saccharide Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962864413P | 2019-06-20 | 2019-06-20 | |
| US62/864,413 | 2019-06-20 | ||
| PCT/US2020/038760 WO2020257665A1 (en) | 2019-06-20 | 2020-06-19 | Azacitidine in combination with venetoclax, gilteritinib, midostaurin or other compounds for treating leukemia or myelodysplastic syndrome |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3143711A1 true CA3143711A1 (en) | 2020-12-24 |
Family
ID=71528047
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3143711A Pending CA3143711A1 (en) | 2019-06-20 | 2020-06-19 | Azacitidine in combination with venetoclax, gilteritinib, midostaurin or other compounds for treating leukemia or myelodysplastic syndrome |
| CA3143719A Pending CA3143719A1 (en) | 2019-06-20 | 2020-06-19 | Azacitidine in combination with venetoclax, gilteritinib, midostaurin or other compounds for treating leukemia or myelodysplastic syndrome |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3143719A Pending CA3143719A1 (en) | 2019-06-20 | 2020-06-19 | Azacitidine in combination with venetoclax, gilteritinib, midostaurin or other compounds for treating leukemia or myelodysplastic syndrome |
Country Status (11)
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2841572B1 (en) | 2012-04-27 | 2019-06-19 | Duke University | Genetic correction of mutated genes |
| US9828582B2 (en) | 2013-03-19 | 2017-11-28 | Duke University | Compositions and methods for the induction and tuning of gene expression |
| US10676726B2 (en) | 2015-02-09 | 2020-06-09 | Duke University | Compositions and methods for epigenome editing |
| WO2017066497A2 (en) | 2015-10-13 | 2017-04-20 | Duke University | Genome engineering with type i crispr systems in eukaryotic cells |
| US12214054B2 (en) | 2015-11-30 | 2025-02-04 | Duke University | Therapeutic targets for the correction of the human dystrophin gene by gene editing and methods of use |
| EP3443081A4 (en) | 2016-04-13 | 2019-10-30 | Duke University | CRISPR / CAS9-BASED REPRESSORS FOR IN VIVO SHUT-OFF OF GEN-TARGETS AND METHOD OF USE |
| JP7490211B2 (ja) | 2016-07-19 | 2024-05-27 | デューク ユニバーシティ | Cpf1に基づくゲノム編集の治療適用 |
| US12509492B2 (en) | 2018-01-19 | 2025-12-30 | Duke University | Genome engineering with CRISPR-Cas systems in eukaryotes |
| TWI887234B (zh) | 2019-04-14 | 2025-06-21 | 美國公爵大學 | 治療杜興氏(duchenne)肌肉失養症之大型突變熱點之aav載體介導之刪除 |
| WO2022187288A2 (en) * | 2021-03-01 | 2022-09-09 | Duke University | Systems and methods for genome-wide annotation of gene regulatory elements linked to cell fitness |
| JP7898763B2 (ja) * | 2021-04-05 | 2026-08-03 | ピノットバイオ インコーポレイテッド | 4’-チオ-5-アザ-2’-デオキシシチジンおよびベネトクラクスの併用療法 |
| WO2022240788A1 (en) * | 2021-05-11 | 2022-11-17 | Abbvie Inc. | Venetoclax dosing regimens for use in treating myelodysplastic syndromes in combination with a cyp3a inhibitor and azacitidine |
| BR112023023677A2 (pt) * | 2021-05-11 | 2024-02-20 | Abbvie Inc | Regimes de dosagem de venetoclax para o uso no tratamento de síndromes mielodisplásicas em combinação com azacitidina |
| US20250312327A1 (en) * | 2021-10-14 | 2025-10-09 | Pharos Ibio Co., Ltd | Composition for combination therapy, comprising 2,3,5-substituted thiophene compound |
| WO2023129667A1 (en) | 2021-12-30 | 2023-07-06 | Biomea Fusion, Inc. | Pyrazine compounds as inhibitors of flt3 |
| CA3260237A1 (en) | 2022-06-24 | 2023-12-28 | Tune Therapeutics, Inc. | Compositions, systems and methods for reducing low-density lipoprotein by targeted gene repression |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK3782612T3 (da) | 2008-05-15 | 2024-01-15 | Celgene Corp | Orale formuleringer af cytidinanaloger og fremgangsmåder til anvendelse deraf |
| WO2015168466A1 (en) | 2014-05-01 | 2015-11-05 | Quanticel Pharmaceuticals, Inc. | Inhibitors of lysine specific demethylase-1 |
| ES2935114T3 (es) | 2014-09-05 | 2023-03-01 | Celgene Quanticel Res Inc | Inhibidores de la desmetilasa 1 específica de lisina |
| EA201790543A1 (ru) | 2014-09-08 | 2017-07-31 | Селджин Корпорейшн | Способы лечения заболевания или расстройства с использованием составов для перорального применения, содержащих аналоги цитидина, в комбинации с моноклональным антителом к pd1 или pdl1 |
| CA3002029A1 (en) | 2015-10-15 | 2017-04-20 | Celgene Corporation | Combination therapy for treating malignancies |
| MD3362066T2 (ro) | 2015-10-15 | 2022-08-31 | Les Laboratoires Servier Sas | Terapie combinată pentru tratamentul tumorilor maligne |
| MX373363B (es) | 2015-11-05 | 2020-05-21 | Celgene Quanticel Res Inc | Composiciones que comprenden un inhibidor de demetilasa-1 específico de lisina. |
| SG10201913290QA (en) * | 2016-03-15 | 2020-03-30 | Oryzon Genomics Sa | Combinations of lsd1 inhibitors for the treatment of hematological malignancies |
| WO2018106984A1 (en) * | 2016-12-09 | 2018-06-14 | Constellation Pharmaceuticals, Inc. | Markers for personalized cancer treatment with lsd1 inhibitors |
| EP4201399A3 (en) | 2017-06-30 | 2023-08-09 | Celgene Corporation | Compositions and methods of use of 2-(4-chlorophenyl)-n-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl) methyl) -2,2-difluoroacetamide |
| IL271946B (en) * | 2017-07-09 | 2022-09-01 | Biosight Ltd | Combination cancer therapy |
| TWI848030B (zh) * | 2018-12-18 | 2024-07-11 | 比利時商阿根思公司 | Cd70組合治療 |
-
2020
- 2020-06-19 WO PCT/US2020/038772 patent/WO2020257671A1/en not_active Ceased
- 2020-06-19 MX MX2021015993A patent/MX2021015993A/es unknown
- 2020-06-19 JP JP2021575387A patent/JP2022537551A/ja active Pending
- 2020-06-19 CA CA3143711A patent/CA3143711A1/en active Pending
- 2020-06-19 US US17/620,545 patent/US12447171B2/en active Active
- 2020-06-19 CN CN202080057984.0A patent/CN115066243A/zh active Pending
- 2020-06-19 JP JP2021575509A patent/JP2022537384A/ja active Pending
- 2020-06-19 CA CA3143719A patent/CA3143719A1/en active Pending
- 2020-06-19 MX MX2021015992A patent/MX2021015992A/es unknown
- 2020-06-19 AU AU2020297596A patent/AU2020297596A1/en not_active Abandoned
- 2020-06-19 BR BR112021025537A patent/BR112021025537A2/pt not_active IP Right Cessation
- 2020-06-19 WO PCT/US2020/038760 patent/WO2020257665A1/en not_active Ceased
- 2020-06-19 EP EP20737783.9A patent/EP3986404A1/en not_active Withdrawn
- 2020-06-19 KR KR1020227001609A patent/KR20220050874A/ko not_active Ceased
- 2020-06-19 BR BR112021025375A patent/BR112021025375A2/pt active Search and Examination
- 2020-06-19 KR KR1020227001605A patent/KR20220024639A/ko not_active Ceased
- 2020-06-19 CN CN202080058723.0A patent/CN114727996A/zh active Pending
- 2020-06-19 EP EP20737778.9A patent/EP3986403A1/en active Pending
- 2020-06-19 US US17/620,541 patent/US20220249528A1/en active Pending
- 2020-06-19 AU AU2020296179A patent/AU2020296179A1/en not_active Abandoned
-
2021
- 2021-12-19 IL IL289115A patent/IL289115A/en unknown
- 2021-12-19 IL IL289110A patent/IL289110A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US12447171B2 (en) | 2025-10-21 |
| KR20220024639A (ko) | 2022-03-03 |
| MX2021015993A (es) | 2022-04-06 |
| AU2020296179A1 (en) | 2022-02-03 |
| JP2022537551A (ja) | 2022-08-26 |
| BR112021025537A2 (pt) | 2022-03-03 |
| WO2020257671A1 (en) | 2020-12-24 |
| KR20220050874A (ko) | 2022-04-25 |
| CN115066243A (zh) | 2022-09-16 |
| JP2022537384A (ja) | 2022-08-25 |
| EP3986403A1 (en) | 2022-04-27 |
| CN114727996A (zh) | 2022-07-08 |
| IL289115A (en) | 2022-02-01 |
| MX2021015992A (es) | 2022-04-06 |
| US20220249529A1 (en) | 2022-08-11 |
| EP3986404A1 (en) | 2022-04-27 |
| WO2020257665A1 (en) | 2020-12-24 |
| CA3143719A1 (en) | 2020-12-24 |
| BR112021025375A2 (pt) | 2022-02-01 |
| AU2020297596A1 (en) | 2022-02-03 |
| US20220249528A1 (en) | 2022-08-11 |
| IL289110A (en) | 2022-02-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20220249528A1 (en) | Azacitidine in combination with venetoclax, gilteritinib, midostaurin or other compounds for treating leukemia or myelodysplastic syndrome | |
| Owonikoko et al. | A phase 1 safety study of veliparib combined with cisplatin and etoposide in extensive stage small cell lung cancer: A trial of the ECOG–ACRIN Cancer Research Group (E2511) | |
| JP7445893B2 (ja) | ヒトにおける固形腫瘍の処置のためのC.novyi | |
| TW201840337A (zh) | 使用hsp90抑制劑治療癌症的方法 | |
| JP6833816B2 (ja) | 骨髄腫を治療するためのセルデュラチニブ(cerdulatinib) | |
| US20180353602A1 (en) | Combination of hdac inhibitor and anti-pd-l1 antibody for treatment of cancer | |
| TW202332431A (zh) | 用於治療癌症之方法及包含cdk2抑制劑及cdk4抑制劑之給藥方案 | |
| CA2914310A1 (en) | Pharmaceutical combinations | |
| TW202313039A (zh) | Pm14用途與方案 | |
| WO2020128894A1 (en) | Combinations of a hdm2-p53 interaction inhibitor and a bcl2 inhibitor and their use for treating cancer | |
| Lewin et al. | A phase 1b trial of selinexor, a first-in-class selective inhibitor of nuclear export (SINE), in combination with doxorubicin in patients with advanced soft tissue sarcomas (STS) | |
| Nehra et al. | Olutasidenib: A ray of hope in the treatment of acute myeloid leukaemia | |
| JP2025509278A (ja) | 小細胞肺癌を治療する方法 | |
| JP2014526564A (ja) | 化学療法抵抗性癌の併用療法 | |
| US20260076970A1 (en) | Cancer treatment using mtdp inhibitors and plk1 inhibitors | |
| WO2008070100A1 (en) | Compositions including triciribine and epidermal growth factor receptor inhibitor compounds or salts thereof and methods of use thereof | |
| WO2008060581A2 (en) | Compositions including triciribine and trastuzumab and methods of use thereof | |
| KR20230044452A (ko) | 암을 치료하기 위한 bcl-2 억제제 및 저메틸화제의 조합물, 이의 용도 및 약학적 조성물 | |
| CA2724246A1 (en) | Anticancer combination therapy including triciribine | |
| DK2994126T3 (en) | Combination of a PI3 kinase inhibitor with paclitaxel for use in the treatment or prevention of head and neck cancer | |
| HK40126790A (en) | Treatment of cancers having mutations in wnt pathway tumour suppressors | |
| Thomas et al. | Second-Generation Protein Kinase Inhibitor A Focus on Quizartinib, A Promising Targeted Therapy for High-Risk FLT3+ Patients with Acute Myeloid Leukemia | |
| Parmar et al. | Cancer Chemotherapy: Recent Developments in Hematology Oncology | |
| WO2008070136A1 (en) | Compositions including triciribine and one or more platinum compounds and methods of use thereof | |
| Fuerst | Targeted Therapies Show Impressive Results in Relapsed/Refractory CLL |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED Effective date: 20240821 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20240821 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20241002 |
|
| D00 | Search and/or examination requested or commenced |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT Effective date: 20241015 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20241015 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20241015 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20250331 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT Effective date: 20250430 |
|
| D15 | Examination report completed |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT Effective date: 20250702 |
|
| B12 | Application deemed to be withdrawn, abandoned or lapsed |
Free format text: ST27 STATUS EVENT CODE: N-6-6-B10-B12-B303 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO AN EXAMINER'S REQUISITION Effective date: 20251103 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20251209 |
|
| U13 | Renewal or maintenance fee not paid |
Free format text: ST27 STATUS EVENT CODE: N-2-6-U10-U13-U300 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO MAINTENANCE FEE NOTICE Effective date: 20260209 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20260708 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20260804 |